Zoetis Inc. (NYSE:ZTS) Shares Purchased by Burling Wealth Partners LLC

Burling Wealth Partners LLC grew its position in Zoetis Inc. (NYSE:ZTS - Free Report) by 76.6% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 22,220 shares of the company's stock after acquiring an additional 9,639 shares during the quarter. Burling Wealth Partners LLC's holdings in Zoetis were worth $3,659,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also added to or reduced their stakes in the company. Navigoe LLC bought a new position in shares of Zoetis during the 4th quarter valued at approximately $30,000. Cornerstone Planning Group LLC increased its position in shares of Zoetis by 79.3% during the 1st quarter. Cornerstone Planning Group LLC now owns 199 shares of the company's stock valued at $30,000 after purchasing an additional 88 shares during the last quarter. Murphy & Mullick Capital Management Corp bought a new position in shares of Zoetis during the 4th quarter valued at approximately $44,000. Sound Income Strategies LLC increased its position in shares of Zoetis by 141.4% during the 1st quarter. Sound Income Strategies LLC now owns 280 shares of the company's stock valued at $46,000 after purchasing an additional 164 shares during the last quarter. Finally, Bfsg LLC increased its position in shares of Zoetis by 614.6% during the 1st quarter. Bfsg LLC now owns 293 shares of the company's stock valued at $48,000 after purchasing an additional 252 shares during the last quarter. Institutional investors own 92.80% of the company's stock.

Insider Activity at Zoetis

In other Zoetis news, EVP Roxanne Lagano sold 652 shares of the stock in a transaction dated Tuesday, June 3rd. The stock was sold at an average price of $170.00, for a total value of $110,840.00. Following the completion of the sale, the executive vice president directly owned 15,129 shares in the company, valued at approximately $2,571,930. This trade represents a 4.13% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 0.18% of the company's stock.

Zoetis Stock Down 1.0%

Shares of ZTS stock traded down $1.54 during mid-day trading on Thursday, hitting $150.00. The stock had a trading volume of 3,575,244 shares, compared to its average volume of 2,610,616. Zoetis Inc. has a 12-month low of $139.70 and a 12-month high of $200.33. The firm has a market capitalization of $66.78 billion, a P/E ratio of 26.93, a price-to-earnings-growth ratio of 2.51 and a beta of 0.91. The firm's 50-day moving average is $161.24 and its two-hundred day moving average is $161.62. The company has a debt-to-equity ratio of 1.12, a current ratio of 1.74 and a quick ratio of 1.04.

Zoetis (NYSE:ZTS - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The company reported $1.48 EPS for the quarter, topping the consensus estimate of $1.40 by $0.08. The firm had revenue of $2.22 billion during the quarter, compared to analyst estimates of $2.20 billion. Zoetis had a return on equity of 55.48% and a net margin of 27.12%. The business's revenue for the quarter was up 1.4% compared to the same quarter last year. During the same period in the previous year, the company posted $1.38 EPS. On average, analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, September 3rd. Stockholders of record on Friday, July 18th will be given a $0.50 dividend. This represents a $2.00 annualized dividend and a dividend yield of 1.33%. The ex-dividend date of this dividend is Friday, July 18th. Zoetis's payout ratio is 35.91%.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on ZTS. Piper Sandler boosted their target price on Zoetis from $205.00 to $210.00 and gave the company an "overweight" rating in a research report on Monday, May 12th. UBS Group dropped their price objective on Zoetis from $189.00 to $170.00 and set a "neutral" rating for the company in a report on Wednesday, May 7th. Leerink Partners cut Zoetis from an "outperform" rating to a "market perform" rating and dropped their price objective for the company from $180.00 to $155.00 in a report on Thursday. Finally, Stifel Nicolaus cut Zoetis from a "buy" rating to a "hold" rating and dropped their price objective for the company from $165.00 to $160.00 in a report on Wednesday, June 18th. Three investment analysts have rated the stock with a hold rating, six have given a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $204.63.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.